Immune checkpoint molecules, including inhibitory and stimulatory immune checkpoint
molecules, are defined as ligand–receptor pairs that exert inhibitory or stimulatory effects on …

Harnessing the power of the immune system to recognize and eliminate cancer cells is a
longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune …

Immune checkpoint blockade therapy has been successful in treating some types of cancer
but has not shown clinical benefits for treating leukaemia. This result suggests that …

Inhibitory leukocyte immunoglobulin-like receptors (LILRBs 1-5) transduce signals via
intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that recruit protein …

The effective treatment of acute myeloid leukemia (AML) is very challenging. Due to the
immense heterogeneity of this disease, treating it using a “one size fits all” approach is …

Myeloid cells encounter stromal cells and their matrix determinants on a continual basis
during their residence in any given organ. Here, we examined the impact of the collagen …

Leukocyte immunoglobulin-like receptor B (LILRB), a family of immune checkpoint
receptors, contributes to acute myeloid leukemia (AML) development, but the specific …

Acute myeloid leukemia (AML) is initiated and sustained by a hierarchy of leukemia stem
cells (LSCs), and elimination of this cell population is required for curative therapies. Here …

How particular bone marrow niche factors contribute to the leukemogenic activities of
leukemia-initiating cells (LICs) remains largely unknown. Here, we showed that ATP levels …

Effective eradication of leukemic stem cells (LSCs) remains the greatest challenge in
treating acute myeloid leukemia (AML). The immune receptor LAIR-1 has been shown to …